Baseline characteristics
| Enzalutamide+PROSTVAC | Enzalutamide | All Patients | |
| Number of Patients | 19 | 19 | 38 |
| Median Age (Range) | 64.4 years (56–79) | 68 years (54–87) | 64.6 (54–87) |
| Gleason | |||
| 6 | 1 | 5 | 6 |
| 7 | 9 | 6 | 15 |
| 8–10 | 9 | 8 | 17 |
| Median PSA (Range) | 3.94 ng/dL (2.02–19.43) | 4.49 ng/dL (2.25–16.75) | 4.38 ng/dL (2.02–19.43) |
| Median PSA Doubling Time (Range) | 3.3 months (0.9–7.8) | 5.2 months (1.6–10.3) | 4.1 months (0.9–10.3) |
| Median Testosterone (Range) | 314 ng/dL (182-472) | 317 ng/dL (167-723) | 316 ng/dL (167-723) |
| Previous ADT (Percent) | 7 (37%) | 7 (37%) | 14 (37%) |